Zetia (Ezetimibe) Global Regulatory Status: FDA Approval, EMA Authorization, and Post-Market Safety

What the FDA approved

Zetia is single-ingredient ezetimibe 10 mg, an oral tablet sold by prescription only. NDA 021445 lists an original approval date of October 25, 2002, the brand now sits with Organon, and many generic versions are marketed [1].

The label dated November 25, 2025 gives these indications [1]: adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), with a statin or alone when other LDL-C lowering therapy is not possible; children 10 and older with HeFH, with a statin; adults with mixed hyperlipidemia, with fenofibrate; adults and children 10 and older with homozygous familial hypercholesterolemia, with a statin and other LDL-C lowering therapies; and adults and children 9 and older with homozygous sitosterolemia, to lower sitosterol and campesterol.

Those apply to the single-ingredient tablet. Ezetimibe/simvastatin (Vytorin) is a separate application, NDA 021687, first approved July 23, 2004 [3]. Rosuvastatin/ezetimibe and bempedoic acid/ezetimibe (Nexlizet) are separate products with their own labels [1].

Does the label claim fewer heart attacks or strokes?

No. The Zetia label contains no cardiovascular risk-reduction indication and does not mention IMPROVE-IT [1]. Its stated purpose is lowering LDL-C, and in homozygous sitosterolemia lowering plant sterols [1].

What IMPROVE-IT tested

IMPROVE-IT compared simvastatin 40 mg plus ezetimibe 10 mg with simvastatin 40 mg plus placebo in 18,144 patients hospitalized for acute coronary syndrome within the preceding 10 days [2]. Median follow-up was 6 years. The time-weighted average LDL-C was 53.7 mg/dL with the combination versus 69.5 mg/dL with simvastatin alone [2]. The primary endpoint combined cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization at least 30 days after randomization, and nonfatal stroke. At 7 years its Kaplan-Meier rate was 32.7% with the combination versus 34.7% with simvastatin alone, an absolute difference of 2.0 percentage points (hazard ratio 0.936, 95% CI 0.89 to 0.99) [2]. That result belongs to ezetimibe added to simvastatin; ezetimibe on its own has no outcomes claim in its label [1].

What the label lists for safety

In 10 placebo-controlled monotherapy trials (2,396 patients on ezetimibe 10 mg versus 1,159 on placebo, median 12 weeks), upper respiratory tract infection occurred in 4.3% versus 2.5%, diarrhea in 4.1% versus 3.7%, and arthralgia in 3.0% versus 2.2% [1]. With a statin (11,308 versus 9,361 patients), nasopharyngitis occurred in 3.7% versus 3.3% and myalgia in 3.2% versus 2.7% [1].

There is no boxed warning [1]. Consecutive transaminase rises of 3 times the upper limit of normal or more occurred in 1.3% of patients given ezetimibe with a statin versus 0.4% given a statin alone. The label says to test liver enzymes as clinically indicated and to consider stopping ezetimibe if ALT or AST stay at 3 times the upper limit or higher [1]. Myopathy and rhabdomyolysis are listed as possible, and in post-marketing reports most patients who developed rhabdomyolysis were also taking a statin or another agent such as a fibrate [1]. The label states that human pregnancy data are insufficient, that there are no human lactation data, and that ezetimibe is not recommended in moderate or severe hepatic impairment, where total ezetimibe exposure rises about 3- to 4-fold [1].